Download PDF
Dtsch Med Wochenschr 2000; 125(47): 1435-1438
DOI: 10.1055/s-2000-8490
Der Arzneistoff
© Georg Thieme Verlag Stuttgart · New York

Methotrexat

Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Methotrexat (MTX) wird seit Ende der 40er Jahre in der Chemotherapie maligner Erkrankungen verwandt. Seit den 80er Jahren findet MTX als Basistherapeutikum der rheumatoiden Arthritis (RA) eine zunehmende Verbreitung [1]. Das Wissen über Nutzen und Risiko einer langfristigen Behandlung und über den molekularen Wirkmechanismus nimmt stetig zu. Chemisch ist MTX der Folsäure nahe verwandt [Abb. 1].

Literatur

  • 1 Songsiridej N, Furst D E. Methotrexate - the rapidly acting drug.  Bailliere’s Clin Rheumatol. 1990;  4 575-593
    Google Scholar
  • 2 Cronstein B N. Molecular therapeutics. Methotrexate and its mechanism of action.  Arthritis Rheum. 1996;  39 1951-1960
    Google Scholar
  • 3 Yukioka K, Wakitani S, Yukioka M, Furumitsu Y, Shichikawa K, Ochi T, Goto H, Matsui-Yuasa I, Otani S, Nishizawa Y, Morii H. Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis.  J Rheumatol. 1992;  19 689-692
    Google Scholar
  • 4 Flescher E, Bowlin T L, Ballester A, Houk R, Talal N. Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis.  J Clin Invest. 1989;  83 1356-1362
    Google Scholar
  • 5 Nesher G, Moore T L. The in vitro effects of methotrexate on peripheral blood mononuclear cells: Modulation by methyl donors and spermidine.  Arthritis Rheum. 1990;  33 54-959
    Google Scholar
  • 6 Baggot J E, Vaughn W H, Hudson B B. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5‘-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide.  Biochem J. 1986;  236 193-200
    Google Scholar
  • 7 Cronstein B N, Eberle M A, Gruber H E, Levin R I. Methotrexate inhibits neutrophil function by stimulatin adenosine release from connective tissue cells.  Proc Natl Acad Sci USA. 1991;  88 2441-2445
    Google Scholar
  • 8 Cronstein B N, Daguma L, Nichols D, Hutchison A J, Williams M. The adenosine/neutrophil paradox resolved: Human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 - generation, respectively.  J Clin Invest. 1990;  85 1150-1157
    Google Scholar
  • 9 Cronstein B N, Levin R I, Philips M, Hirschhorn R, Abramson S B, Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors.  J Immunol. 1992;  148 2201-2206
    Google Scholar
  • 10 Parmely M J, Zhou W W, Edwards CK I II, Borcherding D R, Silverstein R, Morrison D C. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge.  J Immunol. 1993;  151 389-396
    Google Scholar
  • 11 Bouma M G, Stad R K, van den Wildenberg F AJM, Buurman W A. Differential regulatory effects of adenosine on cytokine release by activated human monocytes.  J Immunol. 1994;  153 4159-4168
    Google Scholar
  • 12 Sajjadi F G, Takabayashi K, Foster A C, Domingo R C, Firestein G S. Inhibition of TNF-α expression by adenosine: Role of A3 adenosine receptors.  J Immunol. 1996;  156 3435-3442
    Google Scholar
  • 13 Le Moine O, Stordeur P, Schandene L, Marchant A, De Groote D, Goldman M, Deviere J. Adenosine enhances IL-10 secretion by human monocytes.  J Immunol. 1996;  156 4408-4414
    Google Scholar
  • 14 Boyle D L, Sajjadi F G, Firestein G S. Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation.  Arthritis Rheum. 1996;  39 923-930
    Google Scholar
  • 15 Marrill J T, Shen C, Schreibman D, Coffey D, Zakharenko O, Fisher R, Lahita R G, Salmon J, Cronstein B N. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: A mechanism for methotrexate-induced nodulosis in rheumatoid arthritis.  Arthritis Rheum. 1997;  40 1308-1315
    Google Scholar
  • 16 Falcini F, Taccetti G, Ermini M, Trapani S, Calzolari A, Franchi A, Cerinic M M. Methotrexate-associated appearance and rapid progression of rheumatoid nodules in sysemic-onset juvenile rheumatoid arthritis.  Arthritis Rheum. 1997;  40 175-178
    Google Scholar
  • 17 Segal R, Caspi D, Tishler M, Fishel B, Yaron M. Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis.  Arthritis Rheum. 1988;  31 1182-1185
    Google Scholar
  • 18 Wagener P. Die Häufigkeit einer akralen Nodulosis unter Methotrexat-Langzeittherapie bei Patienten mit entzündlich-rheumatischen Erkrankungen. Z.  Rheumatol. 1994;  53 346-350
    Google Scholar
  • 19 Herman R A, Veng-Pedersen P, Hoffman J, Koehnke R, Furst D E. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients.  J Pharm Sci. 1989;  78 165-171
    Google Scholar
  • 20 Lebbe C, Beyeler C, Gerber N J, Reichen J. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis.  Ann Rheum Dis. 1994;  53 475-477
    Google Scholar
  • 21 Claudepierre P, Urien S, Chevalier X, Chassany O, Larget-Piet B, Tillement J -P. Methotrexate serum binding in rheumatoid arthritis.  Int J Clin Pharmacol Ther. 1994;  32 113-115
    Google Scholar
  • 22 Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin.  Pharmacokinet. 1996;  30 194-210
    Google Scholar
  • 23 Kremer J M, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates.  Arthritis Rheum. 1986;  29 832-835
    Google Scholar
  • 24 Schilsky R L. Methotrexate: An effective agent for treating cancer and building careers. The polyglutamate era.  Stem cells. 1996;  14 29-32
    Google Scholar
  • 25 Pourel J, Guillemin F, Fener P, Webanck L, Bene M C, Delorme N. Delayed methotrexate pneumonitis in rheumatoid arthritis.  J Rheumatol. 1991;  18 303-304
    Google Scholar
  • 26 Nuernberg B, Koehnke R, Solsky M, Hoffman J, Furst D E. Biliary elimination of low-dose methotrexate in humans.  Arthritis Rheum. 1990;  33 898-902
    Google Scholar
  • 27 American College of Rheumatology ad hoc Committee on Clinical Guidelines . Guidelines for the management of rheumatoid arthritis.  Arthritis Rheum. 1996;  39 713-722
    Google Scholar
  • 28 Felson D T, Andersson J J, Meenan R F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: Results of two metaanalyses.  Arthritis Rheum. 1990;  33 1449-1461
    Google Scholar
  • 29 Boffa M J, Chalmers R JG. Methotrexate for psoriasis.  Clin Exp Dermatol. 1996;  21 399-408
    Google Scholar
  • 30 Kaye S A, Isenberg D A. Treatment of polymyositis and dermatomyositis.  Br J Hosp Med. 1994;  52 463-468
    Google Scholar
  • 31 Villalba L, Adams E M. Update on therapy for refractory dermatomyositis and polymyositis.  Curr Opin Rheumatol. 1996;  8 544-551
    Google Scholar
  • 32 Sneller M C, Hoffman G S, Talar-Williams C, Kerr G S, Hallahan C W, Fauci A S. An analysis of fourty-two Wegener’s granulomatosis patients treated with methotrexate and prednisone.  Arthritis Rheum. 1995;  38 608-613
    Google Scholar
  • 33 Hoffman G S, Leavitt R Y, Kerr G S, Rottem M, Sneller M C, Fauci A S. Treatment of glucocorticoid-resistant or relapsing Takayasu arteriitis with methotrexate.  Arthritis Rheum. 1994;  37 578-582
    Google Scholar
  • 34 Van den Hoogen F HJ, Boerbooms A MT, Swaak A JG, Rasker J J, van Lier H JJ, van de Putte L BA. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double blind trial, followed by a 24 week observational trial.  Br J Rheumatol. 1996;  35 364-372
    Google Scholar
  • 35 Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross W L. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis.  Rheumatol Int. 1996;  15 195-200
    Google Scholar
  • 36 Schnabel A, Reinhold-Keller E, Gross W L. Risikoprofil von niedrigdosiertem Methotrexat in der Therapie der chronischen Polyarthritis.  Dtsch Med Wschr. 1992;  117 1116-1121
    Google Scholar
  • 37 Walker A M, Funch D, Dreyer N A, Tolman K G, Kremer J M, Alarcon G S, Lee R G, Weinblatt M E. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis.  Arthritis Rheum. 1993;  36 329-335
    Google Scholar
  • 38 Hilliquin P, Renoux M, Perrot S, Puechal X, Menkes C J. Occurence of pulmonary complications during methotrexate therapy in rheumatoid arthritis.  Brit J Rheumatol. 1996;  35 441-445
    Google Scholar
  • 39 Golden M R, Katz R S, Balk R A, Golden H E. the relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis.  J Rheumatol. 1995;  22 1043-1047
    Google Scholar
  • 40 Gutierrez-Urena S, Molina J F, Garcia C O, Cuellar M L, Espinoza L R. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis.  Arthritis Rheum. 1996;  39 272-276
    Google Scholar
  • 41 Schröder J O, Schwab U M, Schnabel A, Asbeck F, Zurborn K H, Gross W L, Euler H H. Häufung MTX-assoziierter Zytopenien bei älteren Patienten.  Dtsch Ärzteblatt. 1996;  93 321-322
    Google Scholar
  • 42 Bleyer W A. Methotrexate induced lymphoma? (Editorial).  J Rheumatol. 1988;  25 404-407
    Google Scholar
  • 43 Sibilia J, Cazals-Hatem D, Liote F, Balandraud N, Tebib J, Mariette X. Increased risk of Hodgkin’s disease but not of non-Hodgkin’s lymphoma in patients with rheumatoid arthritis treated with MTX. Results of a 3 year prospective study in France.  Arthritis Rheum. 1999;  42 S82
    Google Scholar
  • 44 Welch G N, Loscalzo J. Homocysteine and atherothrombosis.  New Engl J Med. 1998;  338 1042-1050
    Google Scholar
  • 45 Morgan S L, Baggot J E, Vaughn W H, Austin J S, Veitch T A, Lee J Y, Koopman W J, Krumdieck C L, Alarcon G S. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis.  Ann Intern Med. 1994;  121 833-841
    Google Scholar
  • 46 Shiroky J B, Neville C, Esdaile J M, Choquette D, Zummer M, Hazeltine M, Bykerk V, Kanji M, St-Pierre A, Robidoux L, Borque L. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: Results of a multicenter randomized, double-blind, placebo-controlled trial.  Arthritis Rheum. 1993;  36 795-803
    Google Scholar
  • 47 Morgan S L, Baggott J E, Lee J Y, Alarcon G S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention.  J Rheumatol. 1998;  25 441-446
    Google Scholar
  • 48 Van Meerten E, Verweij J, Schellens J HM. Antineoplastic agents. Drug interactions of clinical significance.  Drug Saf. 1995;  12 168-182
    Google Scholar
  • 49 Groenendal H, Rampen F H. Methotrexate and trimethoprim-sulphamethoxazole - a potentially hazardous combination.  Clin Exp Dermatol. 1990;  15 358-360
    Google Scholar

Dr. med. F. Schröder

Abteilung Kardiologie und Angiologie Medizinische Hochschule Hannover

Carl-Neuberg-Straße 1

30625 Hannover

Prof. Dr. med. J. O. Schroeder

2. Medizinische Klinik und Poliklinik der Christian-Albrechts-Universität

Chemnitzstraße 33

24116 Kiel

      >